A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Inclusion Criteria:

The key inclusion criteria include but are not limited to the following:

• Has recurrent low-grade (Ta) Non-Muscle Invasive Bladder Cancer (NMIBC) in thebladder

• Must have visible tumor by cystoscopy within 12 weeks prior to first dose

• Has intermediate-risk NMIBC defined as 1 or more of the following risk factors:

• Multiple tumors

• >1 occurrence of low-grade NMIBC within 1 year of the current diagnosis atScreening

• Early recurrence (<1 year) of the initial diagnosis of low-grade disease

• Solitary tumor >3 cm

• Failure of prior intravesical treatment

• An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessedwithin 14 days prior to first dose

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

• Newly diagnosed low-grade non-muscle invasive bladder cancer (Ta NMIBC) in thebladder

• Past or current history of high-grade (Ta or T1 or CIS) NMIBC, muscle invasivebladder cancer (MIBC) or metastatic urothelial carcinoma (UC)

• Has a condition that would prohibit normal voiding (or hold bladder voiding for 1 to 2 hours)

• Has history of documented severe dry eye syndrome, severe Meibomian gland disease,and/or blepharitis, or severe corneal disease that prevents and/or delays cornealhealing

• Has active inflammatory bowel disease requiring immunosuppressive medication orprevious history of inflammatory bowel disease (eg, Chron's disease, ulcerativecolitis, or chronic diarrhea)

• Has uncontrolled, significant cardiovascular disease or cerebrovascular disease

• Known additional malignancy that is progressing or has required active treatmentwithin the past 3 years

• History of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids or has current pneumonitis/interstitial lung disease.